Wendy Pettit
Nurse Practitioner · Rochester, NYNPI 1205871589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 569 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$2K
- Alkermes, Inc.$938
- Otsuka America Pharmaceutical, Inc.$859
- Teva Pharmaceuticals USA, Inc.$850
- Lundbeck LLC$802
- plus $4K from 16 others
What the payments were for
- Food & beverage$12,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 102 | $2,627 |
| AbbVie | 119 | $2,491 |
| Alkermes, Inc. | 35 | $938 |
| Otsuka America Pharmaceutical, Inc. | 42 | $859 |
| Teva Pharmaceuticals USA, Inc. | 50 | $850 |
| Lundbeck LLC | 40 | $802 |
| Vanda Pharmaceuticals Inc. | 22 | $737 |
| Sunovion Pharmaceuticals Inc. | 34 | $630 |
| Neurocrine Biosciences, Inc. | 15 | $419 |
| Axsome Therapeutics, Inc. | 26 | $418 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $354 |
| Supernus Pharmaceuticals, Inc. | 22 | $297 |
| Bausch Health US, LLC | 9 | $162 |
| Idorsia Pharmaceuticals US Inc | 8 | $148 |
| Johnson & Johnson | 6 | $134 |
| Corium, LLC | 5 | $99 |
| Acadia Pharmaceuticals Inc | 2 | $67 |
| Avanir Pharmaceuticals, Inc. | 2 | $60 |
| Noven Therapeutics, LLC | 2 | $32 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,176 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 40 | $51,410 |
| CaplytaLumateperone Tosylate | 24 | $45,146 |
| RexultiBrexpiprazole | 11 | $16,276 |
| Lamotrigine ErLamotrigine | 12 | $3,807 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $2,246 |
| Vilazodone Hcl | 11 | $1,112 |
| Prazosin Hcl | 40 | $787 |
| Quetiapine Fumarate | 38 | $640 |
| Methylphenidate Hcl | 20 | $640 |
| Alprazolam ErAlprazolam | 16 | $612 |
| Hydroxyzine Hcl | 24 | $533 |
| Trazodone Hcl | 57 | $437 |
| Mirtazapine | 31 | $430 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 35 | $411 |
| Fluoxetine Hcl | 12 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,491 | $51,41040 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,627 | $45,14624 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $859 | $16,27611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Rochester
- Grace WlasowiczRochester$41K
- Laurie RoweRochester$11K
- Julie SochaRochester$10K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Melissa LevinElmhurst$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.